7 Mar

Walgreens Stock Continues to Fall Due to Multiple Price Cuts

WRITTEN BY Adrian Stevens FEATURED IN Wall Street Ratings and Consumer Discretionary

Walgreens stock continues to fall

Walgreens Boot Alliance (WBA) shares have taken a beating the past few days. Multiple analysts lowered their target price on the stock. On March 6, Morgan Stanley lowered its target price on Walgreens Boots Alliance stock to $67 from $77. On March 4, UBS reduced its target price to $65 from $70, while J.P. Morgan cut its target price to $84 from $91. On March 1, Baird lowered its target price on Walgreens Boots Alliance stock to $67 from $70 per share.

Analysts lowered their target prices after the FDA cracked down on Walgreens for selling tobacco products to minors. Also, pressure on the company’s earnings from price compression and increased reimbursements remained a drag.

Walgreens Stock Continues to Fall Due to Multiple Price Cuts

Walgreens Boots Alliance stock erased most of its gains. The stock has fallen 10.6% on a YTD (year-to-date) basis as of March 6. The stock has fallen 14.2% in the last four trading days. In comparison, CVS Health (CVS) stock has fallen 17.6% YTD, which reflects pressure on its earnings from higher reimbursements.

Analysts’ rating and target price

Among the analysts providing recommendations on Walgreens Boots Alliance stock, 16 recommended a “hold,” nine recommended a “buy,” and three recommended a “sell.” Analysts have a consensus target price of $75 per share on Walgreens Boots Alliance stock, which implies an upside of 22.7% based on its closing price of $61.10 on March 6.

Barring near-term headwinds, Walgreens Boots Alliance stock looks attractive on the valuation front. The stock trades at 8.7x the fiscal 2020 estimated EPS of $7.02, which seems attractive given the projected growth rate of 8.2% during that period and a dividend yield of 2.7%.

Latest articles

Hibbett Sports (HIBB) stock surged 22.3% as of 1:54 PM ET today as the company reported impressive results for fiscal 2019's fourth quarter, which ended on February 2.

Wall Street analysts expect a potential upside of 21.63% for Alexion Pharmaceuticals based on the stock's closing price on March 21.

Today, we got another round of dismal data points from Europe (VGK)(EZU). According to a Markit survey, Germany’s (EWG) March PMI Composite Output Index fell to a 69-month low of 51.5.

On March 21, US crude oil’s implied volatility was 24.9%, which was 6.7% below its 15-day average. Usually, lower implied volatility supports oil prices.

The overall cannabis sector took a hit today amid the broader market's declines. The volatility index (VIX) jumped 17.9%, and the cannabis sector is more sensitive than the market.

The tech-heavy NASDAQ Composite Index (QQQ) is on track to post its 12th weekly gain in 13 weeks.